Nucala

GlaxoSmithKline LLC🇺🇸 United States

FDA Page

Effective Date: Mar 8, 2023
Approval ID: fefb887c-e4ac-431e-8893-e9d1a5a63fea
Products: 3 registered
Version: 20

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab) for injection, for subcutaneous use NUCALA (mepolizumab) injection, for subcutaneous useInitial U.S. Approval: 2015

Quick Stats

Total Products3

Labelers2

Label Sections37

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.